Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development, progression and prognosis of pulmonary fibrosis; 2) systematically evaluate the safety and effectiveness of frozen lung biopsy, surgical lung biopsy/thoracoscopic lung biopsy and other techniques, and to optimize the histological diagnosis method of f-ILD; 3) construct a set of artificial intelligence (AI) evaluation system for quantitative evaluation of pulmonary fibrosis and its severity, and develop application software; 4) excavate and verify important molecular targets for the formation of pulmonary fibrosis and identify biomarkers; 5) combined with clinical phenotype, imaging, pathology and biomarkers to establish f-ILD early recognition and progress model, intervention strategies, guidelines and consensus, and applicated nationwide.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Diagnosed as ILD

Locations
Other Locations
China
China-Japan Friendship Hospital
RECRUITING
Beijing
Contact Information
Primary
Huaping Dai, M.D. Ph.D.
daihuaping@sina.com
0086-10-84206271
Time Frame
Start Date: 2021-12-01
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 10000
Sponsors
Collaborators: Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Institute of Basic Medical Sciences CAMS, National Institute for Occupational Health and Poison Control, Nankai University, Infervision Medical Technology Company Limited, The First Affiliated Hospital of Guangzhou Medical University, Jilin University, Tongji Hospital
Leads: Dai Huaping

This content was sourced from clinicaltrials.gov